Provided by Tiger Trade Technology Pte. Ltd.

Bioventus Inc.

12.98
-0.0800-0.61%
Post-market: 12.980.00000.00%19:30 EDT
Volume:421.81K
Turnover:5.48M
Market Cap:1.09B
PE:16.60
High:13.35
Open:13.28
Low:12.92
Close:13.06
52wk High:15.89
52wk Low:6.26
Shares:84.09M
Float Shares:33.47M
Volume Ratio:0.81
T/O Rate:1.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.7821
EPS(LYR):0.3300
ROE:25.68%
ROA:5.49%
PB:4.78
PE(LYR):39.33

Loading ...

Bravura Solutions Targets AIM Dual Listing to Boost Global Investor Reach

TIPRANKS
·
Jun 30

Bioventus management to meet with Barrington

TIPRANKS
·
Jun 17

Bioventus Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Jun 16

Bioventus Buy Rating Reiterated on Strengthening Fundamentals and Growth Pillars; $15 Price Target Maintained

TIPRANKS
·
Jun 16

Bioventus Shareholders Back Directors and Auditor at 2026 Meeting

TIPRANKS
·
Jun 04

Bioventus holds annual shareholder meeting, elects directors

Reuters
·
Jun 04

Bioventus CFO to join Goldman Sachs Global Healthcare Conference fireside chat

Reuters
·
Jun 02

Bravura Solutions Updates Registered Office Location in Sydney

TIPRANKS
·
Jun 01

Analysts Offer Insights on Healthcare Companies: Bioventus (BVS) and Elanco Animal Health (ELAN)

TIPRANKS
·
May 24

Bioventus Is Maintained at Outperform by Barrington Research

Dow Jones
·
May 22

Bioventus Affirms Outlook After FDA Device Reclassification

TIPRANKS
·
May 22

Bioventus Inc - Reiterates 2026 Financial Guidance - SEC Filing

THOMSON REUTERS
·
May 22

Bioventus Inc - CMS Updates Medicare Fee Schedule for Non-Invasive Bone Growth Stimulators Effective May 18, 2026 - SEC Filing

THOMSON REUTERS
·
May 22

Bioventus Inc - Does Not Expect Material Impact From Exogen Reimbursement Changes in FY2026 - SEC Filing

THOMSON REUTERS
·
May 22

Bioventus Inc - FDA Reclassifies Exogen Ultrasound Bone Healing System to Class Ii Device on April 16, 2026 - SEC Filing

THOMSON REUTERS
·
May 22

FDA reclassifies Bioventus Exogen bone stimulator, CMS updates Medicare billing rules

Reuters
·
May 22

Bioventus Down Nearly 9%, On Pace for Largest Percent Decrease Since May 2025 -- Data Talk

Dow Jones
·
May 21

Bravura Names Group CEO Colin Greenhill to Board as Executive Director

TIPRANKS
·
May 11

Bioventus Reiterated at Buy as Strong FY26 Start, Deleveraging, and Discount Valuation Support Unchanged $15 Price Target

TIPRANKS
·
May 07

Bioventus Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 06